Nilotinib Teva Uk (Nilotinib)

Nilotinib works by selectively inhibiting the BCR‑ABL tyrosine kinase, as well as c‑KIT and PDGFR kinases. This inhibition blocks key signaling pathways that promote proliferation and survival of leukemic cells, leading to reduced tumor growth and increased programmed cell death.

The dose of Nilotinib Teva Uk is individualized by the treating physician. Factors such as disease phase, patient weight, liver and kidney function, and concurrent medications influence the prescribed amount. Patients should follow the specific dosing instructions provided by their healthcare professional.

Safety of Nilotinib during pregnancy and lactation has not been established. It is generally contraindicated and should be avoided unless the potential benefit outweighs the risk. Women of child‑bearing potential are advised to use effective contraception throughout treatment and for a period after discontinuation.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

The primary alternative is imatinib, another BCR‑ABL inhibitor. Nilotinib is more potent and binds with higher affinity, making it effective in some imatinib‑resistant cases. However, it carries a distinct safety profile, including a higher risk of QT prolongation, which requires careful cardiac monitoring.

Store the tablets at or below 25 °C in the original container, protected from moisture and direct light. Keep the product out of reach of children and do not use if the packaging appears damaged. No refrigeration is required for this oral tablet formulation.

Nilotinib Teva Uk is taken orally, usually with a low‑fat meal. Swallow the tablet whole with water; do not crush, chew, or split it unless instructed by a healthcare professional. Patients should follow the dosing schedule prescribed by their clinician and avoid missing doses.

Serious adverse events include QT interval prolongation, severe liver toxicity, pancreatitis, and profound cytopenias such as neutropenia or thrombocytopenia. Patients should seek immediate medical attention if they experience palpitations, jaundice, severe abdominal pain, unusual bleeding, or any signs of cardiac arrhythmia.

Nilotinib should not be used by individuals with known hypersensitivity to nilotinib or any tablet excipients, those with uncontrolled cardiac arrhythmias, significant QT prolongation, or severe hepatic impairment. It is also contraindicated in patients taking prohibited concomitant medicines that strongly affect its metabolism.